Orion Clinical

simbecorioncro.com

Simbec-Orion Group is a full-service, boutique CRO which offers specialist expertise in oncology, rare & orphan diseases, dermatology, respiratory, neurology and infectious diseases and translational medicine. We offer our clients a full spectrum of drug development services from first-in-human Phase I clinical studies through to pivotal Phase III studies and Phase IV post marketing studies. We have expertise in all drug types, dosage forms and delivery mechanisms. Simbec-Orion Group supports its clients’ development programmes with our in-house central laboratories, pharmacovigilance, data management and statistics, IMP management/pharmacy and medical management.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

ILC DOVER BECOMES A PROVIDER OF ASCENT / ENTRY SPACESUITS FOR BOEING'S STARLINER

ILC Dover | May 27, 2022

news image

ILC Dover, the leading provider of spacesuits since the Apollo era, announced that it was selected to be one of two providers of Boeing's Ascent/Entry Suit for the company's Commercial Crew Program and has developed a bespoke AES spacesuit for CST-100 Starliner crews. "We are proud to utilize our expertise to create a new AES for the Starliner spacecraft. Having worked with the Boeing team on the Starliner's landing airbags, which provide a s...

Read More

Research

XTALPI PARTNERS WITH EXCELRA FOR GOSTAR TO ENHANCE ITS INTELLIGENT DIGITAL DRUG DISCOVERY AND DEVELOPMENT PLATFORM

Excelra Knowledge Solutions Pvt Ltd | January 19, 2022

news image

Excelra, a leading global Data & Analytics organization, announced the partnership for its Global Online Structure Activity Relationship Database with XtalPi Inc., an AI-based pharmaceutical biotechnology company reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform. Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc. as part of the partnership. GOSTAR's ADMET data...

Read More

Pharmacy Market

PFIZER COMPLETES ACQUISITION OF BIOHAVEN PHARMACEUTICALS

Pfizer and Biohaven Pharmaceuticals | October 04, 2022

news image

Pfizer Inc. announced the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults. The acquisition brings to Pfizer a portfolio of promising calcitonin gene-related peptide receptor antagonists including Rimegepant Approved in the United States under the trade name NURTEC® ODT, ...

Read More

Pharma Tech

ASAHI KASEI PHARMA TO SPONSOR RESEARCH FOR DRUG DISCOVERY RESEARCH AND TECHNOLOGY: OPEN INNOVATION 2023

Asahi Kasei | October 17, 2022

news image

Asahi Kasei Pharma, subsidiary of diversified Japanese multinational company Asahi Kasei, is publicly calling for new proposals for drug development research as part of its efforts for open innovation to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes and enterprises around the world. The application period begins at 5:00 a.m. GMT on January 5, 2023 and ends at 8:00 a.m. GMT on February 28, 2023. Asahi Kasei Pharm...

Read More
news image

Business Insights

ILC DOVER BECOMES A PROVIDER OF ASCENT / ENTRY SPACESUITS FOR BOEING'S STARLINER

ILC Dover | May 27, 2022

ILC Dover, the leading provider of spacesuits since the Apollo era, announced that it was selected to be one of two providers of Boeing's Ascent/Entry Suit for the company's Commercial Crew Program and has developed a bespoke AES spacesuit for CST-100 Starliner crews. "We are proud to utilize our expertise to create a new AES for the Starliner spacecraft. Having worked with the Boeing team on the Starliner's landing airbags, which provide a s...

Read More
news image

Research

XTALPI PARTNERS WITH EXCELRA FOR GOSTAR TO ENHANCE ITS INTELLIGENT DIGITAL DRUG DISCOVERY AND DEVELOPMENT PLATFORM

Excelra Knowledge Solutions Pvt Ltd | January 19, 2022

Excelra, a leading global Data & Analytics organization, announced the partnership for its Global Online Structure Activity Relationship Database with XtalPi Inc., an AI-based pharmaceutical biotechnology company reinventing the industry's approach to drug research and development with its Intelligent Digital Drug Discovery and Development platform. Excelra will provide ADMET datasets in the GOSTAR database to XtalPi Inc. as part of the partnership. GOSTAR's ADMET data...

Read More
news image

Pharmacy Market

PFIZER COMPLETES ACQUISITION OF BIOHAVEN PHARMACEUTICALS

Pfizer and Biohaven Pharmaceuticals | October 04, 2022

Pfizer Inc. announced the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults. The acquisition brings to Pfizer a portfolio of promising calcitonin gene-related peptide receptor antagonists including Rimegepant Approved in the United States under the trade name NURTEC® ODT, ...

Read More
news image

Pharma Tech

ASAHI KASEI PHARMA TO SPONSOR RESEARCH FOR DRUG DISCOVERY RESEARCH AND TECHNOLOGY: OPEN INNOVATION 2023

Asahi Kasei | October 17, 2022

Asahi Kasei Pharma, subsidiary of diversified Japanese multinational company Asahi Kasei, is publicly calling for new proposals for drug development research as part of its efforts for open innovation to promote pharmaceutical research and development through enhanced cooperation with universities, research institutes and enterprises around the world. The application period begins at 5:00 a.m. GMT on January 5, 2023 and ends at 8:00 a.m. GMT on February 28, 2023. Asahi Kasei Pharm...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us